GoHealth (GOCO) 10-Q 10 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 03, 2022
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-39390
Entity Registrant Name	GoHealth, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-0563805
Entity Address, Address Line One	214 West Huron St.
Entity Address, City or Town	Chicago,
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60654
City Area Code	312
Local Phone Number	386-8200
Title of 12(b) Security	Class A Common Stock,$0.0001 par value per share
Trading Symbol	GOCO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001808220
Class A Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		121,782,131
Class B common stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		199,223,623

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net revenues:
Net revenues	$ 270,593	$ 204,179
Operating expenses:
Cost of revenue	67,923	48,375
Marketing and advertising	84,033	54,484
Customer care and enrollment	78,455	47,094
Technology	12,759	9,617
General and administrative	29,217	19,685
Amortization of intangible assets	23,514	23,514
Total operating expenses	295,901	202,769
Income (loss) from operations	(25,308)	1,410
Interest expense	11,398	8,688
Other (income) expense, net	63	13
Income (loss) before income taxes	(36,769)	(7,291)
Income tax (benefit) expense	472	(31)
Net income (loss)	(37,241)	(7,260)
Net income (loss) attributable to non-controlling interests	(23,758)	(5,173)
Net income (loss) attributable to GoHealth, Inc.	$ (13,483)	$ (2,087)
Net loss per share (Note 7):
Net loss per share of Class A common stock — basic (in dollars per share)	$ (0.12)	$ (0.02)
Net loss per share of Class A common stock — diluted (in dollars per share)	$ (0.12)	$ (0.02)
Weighted-average shares of Class A common stock outstanding — basic (in shares)	116,207	92,343
Weighted-average shares of Class A common stock outstanding — diluted (in shares)	116,207	92,343
Commission
Net revenues:
Net revenues	$ 209,639	$ 173,981
Enterprise
Net revenues:
Net revenues	$ 60,954	$ 30,198

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (37,241)	$ (7,260)
Other comprehensive income (loss):
Foreign currency translation adjustments	(117)	7
Comprehensive income (loss)	(37,358)	(7,253)
Comprehensive income (loss) attributable to non-controlling interests	(23,833)	(5,168)
Comprehensive income (loss) attributable to GoHealth, Inc.	$ (13,525)	$ (2,085)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 129,628	$ 84,361
Accounts receivable, net of allowance for doubtful accounts of $926 in 2022 and $558 in 2021	40,117	17,276
Commissions receivable - current	189,287	268,663
Prepaid expense and other current assets	32,730	58,695
Total current assets	391,762	428,995
Commissions receivable - non-current	947,280	993,844
Operating lease ROU asset	22,044	23,462
Other long-term assets	2,857	3,608
Property, equipment, and capitalized software, net	27,863	24,273
Intangible assets, net	571,154	594,669
Total assets	1,962,960	2,068,851
Current liabilities:
Accounts payable	25,797	39,843
Accrued liabilities	34,724	52,788
Commissions payable - current	56,645	104,160
Short-term operating lease liability	6,249	6,126
Deferred revenue	1,137	536
Current portion of long-term debt	5,270	5,270
Other current liabilities	11,067	8,344
Total current liabilities	140,889	217,067
Non-current liabilities:
Commissions payable - non-current	281,250	274,403
Long-term operating lease liability	18,185	19,776
Long-term debt, net of current portion	662,678	665,115
Total non-current liabilities	962,113	959,294
Commitments and Contingencies (Note 11)
Stockholders’ equity:
Preferred stock – $0.0001 par value; 20,000 shares authorized; no shares issued and outstanding at March 31, 2022 and December 31, 2021.	0	0
Additional paid-in capital	583,323	561,447
Accumulated other comprehensive income (loss)	(101)	(59)
Accumulated deficit	(221,800)	(208,317)
Total stockholders' equity attributable to GoHealth, Inc.	361,125	353,103
Non-controlling interests	498,833	539,387
Total stockholders’ equity	859,958	892,490
Total liabilities and stockholders’ equity	1,962,960	2,068,851
Class A Common Stock
Stockholders’ equity:
Common stock	12	11
Treasury stock – at cost; 169 shares of Class A common stock at March 31, 2022	(329)	0
Class B common stock
Stockholders’ equity:
Common stock	$ 20	$ 21

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Allowance for doubtful accounts	$ 926	$ 558
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Class A Common Stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	1,100,000,000	1,100,000,000
Common stock, shares issued (in shares)	121,944,000	115,487,000
Common stock, shares outstanding (in shares)	121,775,000	115,487,000
Treasury stock, at cost (in shares)	169,000
Class B common stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	581,346,000	587,360,000
Common stock, shares issued (in shares)	199,338,000	205,352,000
Common stock, shares outstanding (in shares)	199,338,000	205,352,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Class A Common Stock	Class B Common Stock	Common StockClass A Common Stock	Common StockClass B Common Stock	Treasury StockClass A Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated DeficitCumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Income (Loss)	Non-Controlling Interest	Non-Controlling InterestCumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2020					84,196	236,997
Beginning balance at Dec. 31, 2020	$ 1,399,155				$ 8	$ 24		$ 399,169	$ (18,802)		$ 17	$ 1,018,739
Beginning balance (Cumulative impact of Topic 842) at Dec. 31, 2020		$ (63)								$ (17)			$ (46)
Beginning balance (Cumulative impact of Topic 326) at Dec. 31, 2020		$ (539)								$ (141)			$ (398)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(7,260)								(2,087)			(5,173)
Issuance of Class A common shares related to share-based compensation plans (in shares)					12
Share-based compensation expense	5,112							5,112
Foreign currency translation adjustment	7										2	5
Forfeitures of Time-Vesting Units (in shares)						(81)
Redemption of LLC Interests (in shares)					14,310	(14,310)
Redemption of LLC Interests	0				$ 2	$ (2)		61,655				(61,655)
Ending balance (in shares) at Mar. 31, 2021					98,518	222,606
Ending balance at Mar. 31, 2021	1,396,412				$ 10	$ 22		465,936	(21,047)		19	951,472
Beginning balance (in shares) at Dec. 31, 2021			115,487	205,352	115,487	205,352
Beginning balance at Dec. 31, 2021	892,490				$ 11	$ 21	$ 0	561,447	(208,317)		(59)	539,387
Beginning balance (in shares) at Dec. 31, 2021							0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(37,241)								(13,483)			(23,758)
Issuance of Class A common shares related to share-based compensation plans (in shares)					513
Share-based compensation expense	5,155							5,155
Foreign currency translation adjustment	(117)										(42)	(75)
Class A common shares repurchased for employee tax withholdings (in share)							(169)
Class A common shares repurchased for employee tax withholdings	(329)						$ (329)
Forfeitures of Time-Vesting Units (in shares)						(70)
Redemption of LLC Interests (in shares)					5,944	(5,944)
Redemption of LLC Interests	0				$ 1	$ (1)		16,721				(16,721)
Ending balance (in shares) at Mar. 31, 2022			121,775	199,338	121,944	199,338
Ending balance at Mar. 31, 2022	$ 859,958				$ 12	$ 20	$ (329)	$ 583,323	$ (221,800)		$ (101)	$ 498,833
Ending balance (in shares) at Mar. 31, 2022			(169)				(169)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities:
Net income (loss)	$ (37,241)	$ (7,260)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Share-based compensation	5,155	5,112
Depreciation and amortization	2,434	1,853
Amortization of intangible assets	23,514	23,514
Amortization of debt discount and issuance costs	664	684
Non-cash lease expense	1,418	1,216
Other non-cash items	(37)	(480)
Changes in assets and liabilities:
Accounts receivable	(22,888)	(1,661)
Commissions receivable	126,024	9,508
Prepaid expenses and other assets	26,659	9,227
Accounts payable	(14,073)	1,570
Accrued liabilities	(18,393)	(783)
Deferred revenue	601	13
Commissions payable	(40,668)	(10,818)
Operating lease liabilities	(1,468)	(1,188)
Other liabilities	2,785	695
Net cash provided by operating activities	54,486	31,202
Investing Activities
Purchases of property, equipment and software	(5,997)	(3,740)
Net cash used in investing activities	(5,997)	(3,740)
Financing Activities
Repayment of borrowings	(1,318)	(1,043)
Debt issuance cost payments	(1,725)	0
Principal payments under finance lease obligations	(62)	(76)
Cash received on advancement to NVX Holdings, Inc.	0	3,395
Net cash (used in) provided by financing activities	(3,105)	2,276
Effect of exchange rate changes on cash and cash equivalents	(117)	7
Increase in cash and cash equivalents	45,267	29,745
Cash and cash equivalents at beginning of period	84,361	144,234
Cash and cash equivalents at end of period	129,628	173,979
Non-cash investing and financing activities:
Purchases of property, equipment and software included in accounts payable	$ 2,734	$ 1,690

Description of Business and Sig

Description of Business and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Description of Business and Significant Accounting Policies	DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES Description of Business GoHealth, Inc. (the “Company”) is a leading health insurance marketplace and Medicare-focused digital health company whose mission is to improve access to healthcare in America. The Company works with insurance carriers to provide solutions to efficiently enroll individuals in health insurance plans. The Company’s proprietary technology platform leverages modern machine-learning algorithms powered by nearly two decades of insurance purchasing behavior to reimagine the optimal process for helping individuals find the best health insurance plan for their specific needs. The Company’s insurance agents leverage the power of its vertically integrated customer acquisition platform to enroll members in Medicare and individual and family plans. Certain of the Company’s operations do business as GoHealth, LLC (“GoHealth”), a wholly owned subsidiary of the Company that was founded in 2001. The Company was incorporated in Delaware on March 27, 2020 for the purpose of facilitating the Company’s initial public offering (“the IPO”) and other related transactions in order to carry on the business of GoHealth Holdings, LLC (formerly known as Blizzard Parent, LLC), a Delaware limited liability company, and its wholly owned subsidiaries (collectively, "GHH, LLC"). Following the IPO and pursuant to a reorganization into a holding company structure, the Company is a holding company and its principal asset is a controlling equity interest in GHH, LLC. As the sole managing member of GHH, LLC, the Company operates and controls all of the business and affairs of GHH, LLC, and through GHH, LLC and its subsidiaries, conducts its business. Basis of Presentation and Significant Accounting Policies In connection with the IPO, the Company became the sole managing member of GHH, LLC and controls the management of GHH, LLC. As a result, the Company consolidates GHH, LLC’s financial results in its Condensed Consolidated Financial Statements and reports a non-controlling interest for the economic interest in GHH, LLC held by the Continuing Equity Owners. Substantially concurrently with the consummation of the IPO, the existing limited liability company agreement of GHH, LLC was amended and restated to, among other things, recapitalize its capital structure by creating a single new class of units (the “common units”) and provide for a right of redemption of common units (subject in certain circumstances to time-based vesting requirements and certain other restrictions) in exchange for, at the Company’s election, cash or newly-issued shares of Class A common stock on a one-for-one basis. In connection with any redemption, the Company will receive a corresponding number of common units, increasing the Company’s total ownership interest in GHH, LLC. Net income and loss is allocated to the Continuing Equity Owners on a pro rata basis, assuming that any Class B common units that are subject to time-based vesting requirements are fully vested. GHH, LLC is a holding company with no operating assets or operations and was formed to acquire a 100% equity interest in Norvax, LLC (“Norvax”). On May 6, 2020, Blizzard Parent, LLC changed its name to GoHealth Holdings, LLC. GHH, LLC owns 100% of Blizzard Midco, LLC, which owns 100% of Norvax. For all of the periods reported in these Condensed Consolidated Financial Statements, GHH, LLC has not and does not have any material operations on a standalone basis, and all of the operations of GHH, LLC are carried out by Norvax. The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, but do not include all information and footnote disclosures required under GAAP for annual financial statements. In the opinion of management, the interim Condensed Consolidated Financial Statements include all adjustments, consisting only of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position, results of operations and cash flows as of the dates and for the periods presented. All intercompany transactions and balances are eliminated in consolidation. Certain prior period amounts have been reclassified to conform with the current period presentation. Effective on December 31, 2021, we lost our emerging growth company ("EGC") status, which accelerated the adoption of Accounting Standards Update (“ASU”) 2016-02, Leases and ASU 2019-11, Financial Instruments – Credit Losses . As a result, we recast our previously reported consolidated financial statements effective January 1, 2021 to reflect the adoption of these standards. Use of Estimates The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities at the date of the Condensed Consolidated Financial Statements, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. There have been no material changes to the Company’s significant accounting policies as discussed in the notes to the Company’s audited consolidated financial statements as of and for the year ended December 31, 2021. Seasonality A greater number of the Company’s Medicare-related health insurance plans are sold in its fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, the Company’s Medicare plan-related commission revenue is typically highest in the Company’s fourth quarter. The majority of the Company’s individual and family health insurance plans are sold in its fourth quarter during the annual open enrollment period as defined under the federal Patient Protection and ACA and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase individual and family health insurance outside of the open enrollment period, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state. As a result, the Company’s individual and family plan-related commission revenue is typically highest in the Company’s fourth quarter. Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842). The guidance specifies that lessees will need to recognize a right-of-use asset and a lease liability for virtually all their leases except those which meet the definition of a short-term lease. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or financing. Classification will be based on criteria that are similar to those applied in current lease accounting, but without explicit bright lines. The Company adopted the new guidance effective January 1, 2021. The Company elected the optional transition method which allows entities to continue to apply historical accounting guidance in the comparative periods presented in the year of adoption. At transition, lessees and lessors may elect to apply a package of practical expedients permitting entities not to reassess: (i) whether any expired or existing contracts are or contain leases; (ii) lease classification for any expired or existing leases and (iii) whether initial direct costs for any expired or existing leases qualify for capitalization under the amended guidance. These practical expedients must be elected as a package and consistently applied. The Company applied the package of practical expedients upon adoption. As a result of adopting this standard, on January 1, 2021, the Company recorded lease liabilities of $29.3 million, right-of-use assets of $28.0 million, and an immaterial cumulative catch-up adjustment to opening equity. The adoption of this new standard did not have a material impact on the Company’s consolidated statements of operations, comprehensive income (loss), or cash flows. The Company has included expanded disclosures on the condensed consolidated balance sheets and in Note 10 to the Condensed Consolidated Financial Statements. In November 2019, the FASB issued ASU 2019-11, Financial Instruments – Credit Losses

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The Company defines fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques the Company uses to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company classifies the inputs used to measure fair value into the following hierarchy: Level 1 Inputs Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Inputs Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3 Inputs Unobservable inputs for the asset or liability. Fair Value Measurements

Goodwill And Intangible Assets,

Goodwill And Intangible Assets, Net	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	GOODWILL AND INTANGIBLE ASSETS, NET Goodwill During 2019, the Company allocated $380.3 million and $6.2 million of the goodwill recognized in connection with the Acquisition to its Medicare—Internal segment and Medicare—External segment, respectively, based on an estimate of the relative fair value of each reportable segment. The Company tests goodwill for impairment at the reporting unit level annually on November 30th and whenever events or circumstances make it more likely than not that an impairment may have occurred. A reporting unit is an operating segment or one level below an operating segment to which goodwill is assigned when initially recorded. The Company has four reporting units, which are the same as its four operating segments. Fourth Quarter 2021 Goodwill Impairment Charges During the annual enrollment period in the fourth quarter of 2021, the Company and the broader industry experienced an increase in consumer shopping which led to lower policy persistency than anticipated and resulted in lower LTV performance. Additionally, operating margins in the fourth quarter of 2021 declined significantly, which was primarily driven by tight labor markets and resulted in higher than expected customer care and enrollment costs. As such and in connection with the Company’s annual and long-range planning process, which coincided with the Company’s annual goodwill impairment test as of November 30, 2021, the Company determined the Medicare— Internal and Medicare— External reporting units’ financial performance were lower than previously anticipated. As a result, the Company’s quantitative goodwill impairment test indicated that the fair values of the Medicare— Internal and Medicare— External reporting units no longer exceeded their carrying values, and the Company recognized goodwill impairment charges of $380.3 million and $6.2 million for the Medicare-Internal and Medicare— External reporting units, respectively, representing the full amount of goodwill associated with these reporting units. The quantitative goodwill impairment test performed by the Company as of November 30, 2021, included significant level 3 fair value estimates and assumptions including, among others, cash flow projections and selecting an appropriate discount rate. There was no impairment of goodwill for the three months ended March 31, 2021. Intangible Assets The gross carrying amounts, accumulated amortization and net carrying amounts of the Company’s definite-lived amortizable intangible assets, as well as its indefinite-lived intangible trade names, are as follows: Mar. 31, 2022 (in thousands) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 496,000 $ 180,686 $ 315,314 Customer relationships 232,000 59,160 172,840 Total intangible assets subject to amortization $ 728,000 $ 239,846 $ 488,154 Indefinite-lived trade names 83,000 Total intangible assets $ 571,154 Dec. 31, 2021 (in thousands) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 496,000 $ 162,971 $ 333,029 Customer relationships 232,000 53,360 178,640 Total intangible assets subject to amortization $ 728,000 $ 216,331 $ 511,669 Indefinite-lived trade names 83,000 Total intangible assets $ 594,669 There was no impairment of intangible assets for the three months ended March 31, 2022 and 2021. As of March 31, 2022, expected amortization expense related to intangible assets for each of the five succeeding years is as follows: (in thousands) Developed Technology Customer Relationships Total Remainder of 2022 $ 53,143 $ 17,400 $ 70,543 2023 70,857 23,200 94,057 2024 70,857 23,200 94,057 2025 70,857 23,200 94,057 2026 49,600 23,200 72,800 Thereafter — 62,640 62,640 Total $ 315,314 $ 172,840 $ 488,154

Long-Term Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Long-Term Debt	LONG-TERM DEBT The Company’s long-term debt consisted of the following: (in thousands) Mar. 31, 2022 Dec. 31, 2021 Term Loan Facilities $ 522,085 $ 523,403 Revolving Credit Facilities 155,000 155,000 Less: Unamortized debt discount and issuance costs (9,137) (8,018) Total debt $ 667,948 $ 670,385 Less: Current portion of long-term debt (5,270) (5,270) Total long-term debt $ 662,678 $ 665,115 Term Loan Facilities On September 13, 2019, Norvax (“the Borrower”) entered into a first lien credit agreement (the “Credit Agreement”) which provided for a $300.0 million aggregate principal amount senior secured term loan facility (the “Initial Term Loan Facility”). During 2020, the Company entered into a series of amendments to the Credit Agreement to provide for, among other items as further described below, $117.0 million of incremental term loans (the “Incremental Term Loan Facility”). On June 11, 2021, the Company entered into Amendment No. 5 to the Credit Agreement and Incremental Facility Agreement (“Amendment No. 5”). Amendment No. 5 created a new class of incremental term loans (the “2021 Incremental Term Loans”) in an aggregate principal amount equal to $310.0 million, which was used to refinance $295.5 million of outstanding principal under the Initial Term Loan Facility, pay the related accrued interest and fund the prepayment premium. In connection with Amendment No. 5 and the refinancing of the Initial Term Loan, the Company recognized an $11.9 million loss on debt extinguishment, representing the 2% prepayment premium of $5.9 million and the write-down of deferred financing costs and debt discounts of $6.0 million. The Company incurred $1.7 million of debt issuance costs associated with Amendment No. 5, which are being amortized over the life of the debt to interest expense using the effective interest method. On November 10, 2021, the Company entered into Amendment No. 6 to the Credit Agreement and Incremental Facility Agreement (“Amendment No. 6”). Amendment No. 6 provided $100.0 million of incremental term loans (the “2021-2 Incremental Term Loans”). The Company incurred $2.5 million of debt issuance costs associated with Amendment No. 6, which are being amortized over the life of the debt to interest expense using the effective interest method. The Company collectively refers to the Initial Term Loan, Incremental Term Loan Facility, the 2021 Incremental Term Loans, and the 2021-2 Incremental Term Loans as the “Term Loan Facilities”. As of March 31, 2022, the Company had a principal amount of $114.7 million, $307.7 million, and $99.7 million outstanding under the Incremental Term Loan Facility, the 2021 Incremental Term Loans, and the 2021-2 Incremental Term Loans, respectively. As of December 31, 2021, the Company had a principal amount of $115.0 million $308.4 million, and $100.0 million outstanding under the Incremental Term Loan Facility, the 2021 Incremental Term Loans, and the 2021-2 Incremental Term Loans, respectively. The Incremental Term Loan Facility effective interest rate was 7.5% at both March 31, 2022 and December 31, 2021. Both the 2021 Incremental Term Loans and the 2021-2 Incremental Term Loans effective interest rate was 7.5% and 6.0% at March 31, 2022 and December 31, 2021, respectively. Borrowings under the Incremental Term Loan Facility are, at the option of the Borrower, either (i) alternate base rate (“ABR”) plus 5.50% per annum or (ii) LIBOR plus 6.50% per annum. The 2021 Incremental Term Loans from and after the 2021-2 Incremental Term Loans Closing Date, or November 10, 2021, and the 2021-2 Incremental Term Loans, bear interest at either (i) ABR plus 4.00% per annum or (ii) LIBOR plus 5.00% per annum. On March 14, 2022, the Company entered into Amendment No. 7 to the Credit Agreement and Incremental Facility Agreement (“Amendment No. 7”). Amendment No. 7 provided that (a) the 2021 Incremental Term Loans, from and after the Amendment No. 7 Effective Date, will bear interest at either (i) ABR plus 5.50% per annum or (ii) LIBOR plus 6.50% per annum and (b) the 2021-2 Incremental Term Loans, from and after the Amendment No. 7 Effective Date, will bear interest at either (i) ABR plus 5.50% per annum or (ii) LIBOR plus 6.50% per annum. Amendment No. 7 further amended the Credit Agreement to remove testing of the Net Leverage Ratio for the December 31, 2021 period and increased the maximum permitted Net Leverage Ratio for future reporting periods through March 31, 2023. The Company incurred $1.7 million of debt issuance costs associated with Amendment No. 7, which are being amortized over the life of the debt to interest expense using the effective interest method. The Term Loan Facilities are payable in quarterly installments in the principal amount of 0.25% of the original principal amount. The remaining unpaid balance on the Term Loan Facilities, together with all accrued and unpaid interest thereon, is due and payable on or prior to September 13, 2025. Revolving Credit Facilities The Credit Agreement provided for a $30.0 million aggregate principal amount senior secured revolving credit facility (the “Revolving Credit Facility”). During 2020, the Company entered into a series of amendments to the Credit Agreement to provide for $28.0 million of incremental revolving credit (the “Incremental Revolving Credit Facilities”). On May 7, 2021, the Company entered into a fourth amendment to the Credit Agreement, which provided $142.0 million of incremental revolving credit (the “Incremental No. 4 Revolving Credit Facility”), for a total amount of $200.0 million. The Company collectively refers to the Revolving Credit Facility, the Incremental Revolving Credit Facilities, and the Incremental No. 4 Revolving Credit Facility as the “Revolving Credit Facilities”. Amendment No. 5, as described above, also separated the Revolving Credit Facilities into two classes of revolving commitments consisting of Class A Revolving Commitments in the amount of $30.0 million and Class B Revolving Commitments in the amount of $170.0 million. Borrowings under the Class A Revolving Commitments bear interest at either ABR plus 5.50% per annum or LIBOR plus 6.50% per annum. Borrowings under the Class B Revolving Commitments bear interest at either ABR plus 3.00% per annum or LIBOR plus 4.00% per annum. The Borrower is required to pay a commitment fee of 0.50% per annum under the Revolving Credit Facilities. The Company had $23.2 million outstanding under the Class A Revolving Credit Facilities and $131.8 million outstanding under the Class B Revolving Credit Facilities as of both March 31, 2022 and December 31, 2021. The Revolving Credit Facilities have a remaining capacity of $45.0 million in the aggregate as of March 31, 2022. The Class A Revolving Credit Facilities and Class B Revolving Credit Facilities effective interest rates at both March 31, 2022 and December 31, 2021 was 7.5% and 5.0%, respectively. Outstanding borrowings under the Revolving Credit Facilities do not amortize and are due and payable on September 13, 2024. The Borrower’s obligations under the Term Loan Facilities and Revolving Credit Facilities are guaranteed by Blizzard Midco, LLC and certain of the Borrower’s subsidiaries. All obligations under the Credit Agreement are secured by a first priority lien on substantially all of the assets of the Borrower, including a pledge of all of the equity interests of its subsidiaries. The Credit Agreement contains customary events of default and financial and non-financial covenants. The Company is in compliance with all covenants as of March 31, 2022.

Stockholders' Equity and Member

Stockholders' Equity and Members' Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders' Equity and Members' Equity	STOCKHOLDERS' EQUITY AND MEMBERS' EQUITY In connection with the Company’s IPO in July 2020, the Company’s Board of Directors approved an amended and restated certificate of incorporation and amended and restated bylaws. The amended and restated certificate of incorporation authorizes the issuance of up to 1,100,000 shares of Class A common stock, 690,000 shares of Class B common stock and 20,000 shares of preferred stock, each having a par value of $0.0001 per share. The number of shares of Class B common stock authorized is reduced for redemptions and forfeitures as they occur. The Company’s amended and restated certificate of incorporation and the GoHealth Holdings, LLC Agreement require that the Company and GoHealth Holdings, LLC at all times maintain a one-to-one ratio between the number of shares of Class A common stock issued by the Company and the number of LLC Interests owned by the Company, except as otherwise determined by the Company. Additionally, the Company’s amended and restated certificate of incorporation and the GoHealth Holdings, LLC Agreement require that the Company and GoHealth Holdings, LLC at all times maintain a one-to-one ratio between the number of shares of Class B common stock owned by the Continuing Equity Owners and their respective permitted transferees and the number of LLC Interests owned by the Continuing Equity Owners and their respective permitted transferees, except as otherwise determined by the Company. Only the Continuing Equity Owners and the permitted transferees of Class B common stock are permitted to hold shares of Class B common stock. Shares of Class B common stock are transferable for shares of Class A common stock only together with an equal number of LLC Interests. Holders of shares of the Company’s Class A common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Each share of Class B common stock entitles its holders to one vote per share on all matters presented to the Company’s stockholders generally. Holders of shares of Class B common stock will vote together with holders of the Company’s Class A common stock as a single class on all matters presented to the Company’s stockholders for their vote or approval, except for certain amendments to the Company’s amended and restated certificate of incorporation or as otherwise required by applicable law or the amended and restated certificate of incorporation. Holders of our Class B common stock are not entitled to participate in any dividends declared by our board of directors. Under the terms of the Company’s amended and restated certificate of incorporation, the Company’s board of directors is authorized to direct the Company to issue shares of preferred stock in one or more series without stockholder approval. The Company’s board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. The Continuing Equity Owners may, subject to certain exceptions, from time to time at each of their options require GoHealth Holdings, LLC to redeem all or a portion of their LLC Interests in exchange for, at the Company’s election (determined by at least two of the Company’s independent directors who are disinterested), newly-issued shares of Class A common stock on a one-for-one basis, or to the extent there is cash available from a secondary offering, a cash payment equal to a volume weighted average market price of one share of the Company’s Class A common stock for each LLC Interest so redeemed, in each case, in accordance with the terms of the GoHealth Holdings, LLC Agreement. The weighted average ownership percentages for the applicable reporting periods are used to attribute net income (loss) and other comprehensive income (loss) to the Company and the non-controlling interest holders. The non-controlling interest holders' weighted average ownership percentages for the three months ended March 31, 2022 and 2021 were 63.8%, and 71.2%, respectively. Upon the Company’s dissolution or liquidation, after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, holders of Class A common stock and Class B common stock will be entitled to receive ratable portions of the Company’s remaining assets available for distribution; provided, that the holders of Class B common stock shall not be entitled to receive more than $0.0001 per share of Class B common stock and upon receiving such amount, shall not be entitled to receive any of the Company’s other assets or funds with respect to such shares of Class B common stock.

Share-Based Compensation Plans

Share-Based Compensation Plans	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Share-Based Compensation Plans	SHARE-BASED COMPENSATION PLANS The following table summarizes share-based compensation expense by operating function for the periods presented: Three months ended Mar. 31, (in thousands) 2022 2021 Marketing and advertising $ 441 $ 337 Customer care and enrollment 631 796 Technology 982 747 General and administrative 3,101 3,232 Total share-based compensation expense $ 5,155 $ 5,112 2021 Employment Inducement Award Plan On December 19, 2021, the Company’s Board of Directors approved the adoption of the GoHealth, Inc. 2021 Employment Inducement Award Plan (the “Inducement Award Plan”). In accordance with Rule 5635(c)(4), awards under the Inducement Award Plan may only be made to a newly hired employee who has not previously been a member of the Board of Directors, or an employee who is being rehired following a bona fide period of non-employment by the Company or a subsidiary, as a material inducement to the employee’s entering into employment with the Company or its subsidiary. An aggregate of 4,000 shares of the Company’s Class A common stock have been reserved for issuance under the Inducement Award Plan. Performance Stock Units (“PSUs”) During 2021, the Company granted to certain of its employees 489 shares of Class A common stock issuable pursuant to PSUs. The criteria for the market-based PSUs is based on the Company’s total shareholder return (“TSR”) relative to the TSR of the common stock of a pre-defined industry peer group. TSR is measured at the end of the performance period, which is generally the period commencing on the grant date and ending on the three-year anniversary of the grant date. Depending on the relative TSR achieved, the number of PSUs earned can vary from 0% of the target award to a maximum of 200% of the target award. The Company estimated the grant-date fair value of the awards subject to a market condition using a Monte Carlo simulation model, using the following weighted-average assumptions: risk-free interest rate of 0.2% and annualized volatility of 72.0%. The grant-date fair value of the PSUs was $22.17. The Company recognizes the grant-date fair value of PSUs as compensation expense on a straight-line basis over the three-year performance period. For the three months ended March 31, 2022 and 2021, the Company recorded share-based compensation expense related to PSUs of $0.9 million and $0.5 million, respectively. 2020 Employee Stock Purchase Plan (“2020 ESPP”) On July 7, 2020, the Company adopted the 2020 Employee Stock Purchase Plan (“ESPP”), which became effective on the same date. The purpose of the 2020 ESPP is to provide the Company's eligible employees with an opportunity to purchase designated shares of the Company’s Class A common stock at a price equal to 85% of the lower of the closing price at the beginning or end of each offering period. During the three months ended March 31, 2022 and 2021, the Company issued no shares of Class A common stock through the ESPP. For the three months ended March 31, 2022 and 2021, the Company recorded share-based compensation expense related to the 2020 ESPP of $0.2 million and $0.1 million, respectively. Stock Option Repricing On April 25, 2022 and in accordance with the terms of the GoHealth, Inc. 2020 Incentive Award Plan, the Company’s Board of Directors approved a stock option repricing (the “Repricing”) where the exercise price of each Relevant Option (as defined below) was reduced to $1.05 per share, the average trailing 20 trading day closing price of the Company’s Class A common stock as of market close on the day of board approval. “Relevant Options” are all outstanding stock options as of April 25, 2022 (vested or unvested) to acquire shares of the Company’s Class A common stock that were issued to currently employed employees prior to April 1, 2022, but excluding stock options granted to certain executive officers. Except for the reduction in the exercise price of the Relevant Options, all outstanding stock options will continue to remain outstanding in accordance with their current terms and conditions. The Company is in the process of determining the incremental compensation cost associated with the Repricing.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	NET LOSS PER SHARE Basic loss per share is computed by dividing net loss attributable to GoHealth, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows: Three months ended Mar. 31, (in thousands, except per share amounts) 2022 2021 Numerator: Net loss $ (37,241) $ (7,260) Less: Net loss attributable to non-controlling interests (23,758) (5,173) Net loss attributable to GoHealth, Inc. (13,483) (2,087) Denominator: Weighted-average shares of Class A common stock outstanding—basic 116,207 92,343 Effect of dilutive securities — — Weighted-average shares of Class A common stock outstanding—diluted 116,207 92,343 Net loss per share of Class A common stock—basic and diluted $ (0.12) $ (0.02) The following number of shares were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive: Mar. 31, (in thousands) 2022 2021 Class A common stock issuable pursuant to equity awards 6,375 6,539 Class B common stock 199,338 222,606 Shares of Class B common stock do not share in earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been presented.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The Company is taxed as a corporation for income tax purposes and is subject to federal, state, and local taxes on the income allocated to it from GHH, LLC based upon the Company’s economic interest in GHH, LLC. The Company is the sole managing member of GHH, LLC and, as a result, consolidates the financial results of GHH, LLC. GHH, LLC is a limited liability company taxed as a partnership for income tax purposes, and the subsidiaries of GHH, LLC are limited liability companies for income tax purposes except for a subsidiary and its foreign subsidiary, which are taxed as a corporation and foreign disregarded entity, respectively. As such, GHH, LLC does not pay any federal income taxes, as income or loss is included in the tax returns of the individual members. Additionally, certain wholly-owned entities taxed as corporations are subject to federal, state, and foreign income taxes in the jurisdictions in which they operate, and accruals for such taxes are included in the Condensed Consolidated Financial Statements. The Company’s effective tax rate for the three months ended March 31, 2022 and 2021 was (1.28)% and 0.43%, respectively. The effective tax rate for each period is lower than the statutory tax rate primarily due to the effect of loss entities for which the Company excludes from its annual effective tax rate calculation and loss attributable to non-controlling interests. Tax Receivable Agreement (“TRA”) In connection with the IPO, the Company entered into a TRA with GHH, LLC, the Continuing Equity Owners and the Blocker Shareholders that will provide for the payment by the Company to the Continuing Equity Owners and the Blocker Shareholders of 85% of the amount of tax benefits, if any, that the Company actually realizes (or in some circumstances is deemed to realize). The amounts payable under the TRA will vary depending upon a number of factors, including the amount, character, and timing of the taxable income of the Company in the future. As of March 31, 2022, the Company has determined there is no resulting liability related to the TRA. Should the Company determine that the TRA liability will be considered probable at a future date based on new information, any changes will be recorded within income from continuing operations at that time.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue	REVENUE Revenue Recognition for Variable Consideration The Company’s variable consideration includes the total estimated lifetime value (“LTV”) it expects to receive for selling an insurance product after the carrier approves an application. The consideration is variable based on the amount of time it estimates a policy will remain in force, which is based on historical experience or carrier experience to the extent available, industry data, and expectations as to future retention rates. Additionally, the Company considers the application of a constraint and only recognizes the amount of variable consideration that it believes is probable that it will be entitled to receive and will not be subject to a significant revenue reversal in the future. Due to lower persistency observed during the three months ended March 31, 2022 and declining LTV estimates, the Company applied an incremental LTV constraint to all Medicare policies sold in the first quarter of 2022. On a quarterly basis, the Company re-estimates LTV at a vintage level for outstanding vintages, reviews and monitors changes in the data used to estimate LTV, as well as the cash received for each vintage as compared to the original estimates. The difference between cash received for each vintage and the respective estimated LTV can be significant and may or may not be indicative of the need to adjust revenue for prior period vintages. Changes in LTV may result in an increase or a decrease to revenue and a corresponding change to commissions receivable. The Company analyzes these differences and to the extent the Company believes differences in the estimates are indicative of a change to prior period LTVs, the Company will adjust revenue for the affected vintages at the time such determination is made and when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. For the three months ended March 31, 2022 and 2021, the Company recorded negative revenue adjustments of $2.6 million and $2.2 million, respectively, for changes in estimates relating to performance obligations satisfied in prior periods. Disaggregation of Revenue The table below depicts the disaggregation of revenue by product, and is consistent with how the Company evaluates its financial performance: Three months ended Mar. 31, (in thousands) 2022 2021 Commission revenue: Medicare: Medicare Advantage $ 206,634 $ 168,148 Medicare Supplement 312 784 Prescription Drug Plans 1,254 553 Total Medicare 208,200 169,485 Individual and Family Plan: Fixed Indemnity 381 2,781 Short-term 171 400 Major Medical 72 201 Total Individual and Family Plan 624 3,382 Ancillary 811 1,108 Small Group 4 6 Total commission revenue 209,639 173,981 Enterprise revenue: Partner Marketing and Enrollment Services 40,664 21,857 Direct Partner Campaigns 20,116 8,102 Other 174 239 Total enterprise revenue 60,954 30,198 Net revenues $ 270,593 $ 204,179 Contract Assets and Liabilities The company records contract assets and contract liabilities from contracts with customers as it relates to commissions receivable, commissions payable and deferred revenue. Commissions receivable represents estimated variable consideration for commissions to be received from insurance carriers for performance obligations that have been satisfied. Commissions payable represents estimated commissions to be paid to the Company’s external agents and other partners. Deferred revenue includes amounts collected for partner marketing and enrollment services and technology licensing and implementation fees in advance of the Company satisfying its performance obligations for such customers. The Company had unbilled receivables for performance-based enrollment fees as of March 31, 2022 and December 31, 2021 of $5.5 million and $20.1 million, respectively, which are recorded in prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets. There are no other contract liabilities or contract assets recorded by the Company. For both the three months ended March 31, 2022 and 2021, the Company recognized $0.1 million of revenue that was deferred as of December 31, 2021 and December 31, 2020, respectively. Commissions Receivable Our contracts with carriers expose us to credit risk as a financial loss could be incurred if the counterparty does not fulfill its financial obligation. While we are exposed to credit losses due to the potential non-performance of our counterparties, we consider the risk of this remote. We estimate our maximum credit risk in determining the commissions receivable amount recorded on the balance sheet. Commissions receivable activity is summarized as follows: Three months ended Mar. 31, (in thousands) 2022 2021 Beginning balance $ 1,262,507 $ 809,859 Commission revenue 209,639 173,981 Cash receipts (335,663) (183,489) Allowance for credit loss 84 6 Ending balance $ 1,136,567 $ 800,357 Less: Commissions receivable - current 189,287 98,157 Commissions receivable - non-current $ 947,280 $ 702,200

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	LEASES Effect of Standard Adoption We adopted ASU 2016-02, Leases (Topic 842), effective January 1, 2021, using the optional transition method which allows entities to continue to apply historical accounting guidance in the comparative periods presented in the year of adoption. We elected the package of practical expedients permitted under the transition guidance within Accounting Standards Codification Topic 842 ("ASC 842") which, among other items, allowed us to carry forward the historical lease classifications. As such, we applied the modified retrospective approach as of the adoption date to those lease contracts for which we have taken possession of the property as of January 1, 2021. Results for reporting periods beginning on or after January 1, 2021 are presented under ASC 842. Upon transition, on January 1, 2021, we recorded the following increases (decreases) to the respective line items on the Consolidated Balance Sheet: (in thousands) Adjustment as of January 1, 2021 Operating lease ROU asset $ 28,044 Property, equipment and capitalized software, net (63) Short-term operating lease liabilities 5,118 Other current liabilities (1,231) Long-term operating lease liabilities 24,156 Accumulated deficit (17) Non-controlling interests (46) Nature of Leases Under ASC 842, we determine if an arrangement is a lease at inception of the arrangement. We have entered into operating and finance lease agreements with lease periods expiring between 2022 and 2032. Operating leases primarily consist of real estate and data centers, and finance leases primarily consist of office equipment. As of January 1, 2021, with the adoption of ASC 842, leases are included in operating lease right-of-use (“ROU”) assets and lease liabilities on our Condensed Consolidated Balance Sheets. Operating lease ROU assets and lease liabilities are recognized at the lease commencement date. Operating lease ROU assets represent our right to use an underlying asset and are based upon the lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. Lease liabilities represent the present value of lease payments over the lease term. The implicit rate within each lease is not readily determinable and therefore we use our incremental borrowing rate at the lease commencement date to determine the present value of the lease payments. The determination of the incremental borrowing rate requires judgement. We determined our incremental borrowing rate for each lease using indicative bank borrowing rates, adjusted for various factors including level of collateralization, term and treasury yield curves to align with the terms of the respective lease. The Company has elected the following practical expedients for all classes of leased assets: • Adopt the short-term lease exception for leases with terms of twelve months or less and account for them as if they were operating leases under ASC 840; and • Apply the practical expedient of combining lease and non-lease components. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We do not include any renewal options in the lease terms for calculating lease liability, as the renewal options allow us to maintain operational flexibility and we are not reasonably certain that we will exercise these renewal options at the time of lease commencement. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term. Components of lease expense are as follows, all recorded within operating expenses in the Condensed Consolidated Statement of Operations: Three months ended Mar. 31, (in thousands) 2022 2021 Finance lease cost (1) $ 61 $ 85 Operating lease cost 1,947 1,796 Short-term lease cost (2) 83 119 Variable lease cost (3) 44 43 Sublease income (275) — Total net lease expense $ 1,860 $ 2,043 (1) Primarily consists of amortization of finance lease right-of-use assets and an immaterial amount of interest on finance lease liabilities recorded in operating expenses and interest expense in the condensed consolidated statements of operations. (2) Includes costs related to leases, which at the commencement date, have a lease term of 12 months or less. (3) Includes costs made by the Company for the right to use an underlying asset that vary because of changes in facts or circumstances occurring after the commencement date, other than the passage of time. On May 12, 2020, the Company entered into a lease agreement with Wilson Tech 5, LLC, for a proposed site in Lindon, Utah, beginning in 2022. The Company will not have access to the leased premises until construction is complete, the “commencement date,” and is not deemed to be the owner during the construction period. This lease agreement expires ten years after the commencement date. The Company did not make any lease payments during the three months ended March 31, 2022 and 2021 under this lease. The initial base annual rent will be approximately $4.6 million beginning in mid-2022. On February 15, 2022, the Company entered into a lease agreement for a site in Slovakia related to our Slovakian operations. The lease is expected to commence on October 1, 2022 with a lease term through March 31, 2030. As of March 31, 2022, future minimum lease payments for finance and operating leases consisted of the following: (in thousands) Finance Leases Operating Leases Remainder of 2022 $ 42 $ 5,666 2023 — 7,584 2024 — 6,406 2025 — 5,039 2026 — 1,929 Thereafter — 859 Total lease payments $ 42 $ 27,483 Less: Imputed interest — (3,049) Present value of lease liabilities $ 42 $ 24,434 Supplemental cash flow information related to leases are as follows: Three months ended Mar. 31, (in thousands) 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 1,832 $ 1,618 Operating cash flows from finance leases $ 1 $ 6 Financing cash flows from finance leases $ 62 $ 76 The weighted average remaining lease term and discount rate are as follows: Three months ended Mar. 31, (in thousands) 2022 2021 Weighted average remaining lease term (in years): Operating leases 3.9 years 4.9 years Finance leases 0.2 years 1.2 years Weighted average discount rate: Operating leases 6.2 % 6.1 % Finance leases 6.5 % 6.5 %
Leases	LEASES Effect of Standard Adoption We adopted ASU 2016-02, Leases (Topic 842), effective January 1, 2021, using the optional transition method which allows entities to continue to apply historical accounting guidance in the comparative periods presented in the year of adoption. We elected the package of practical expedients permitted under the transition guidance within Accounting Standards Codification Topic 842 ("ASC 842") which, among other items, allowed us to carry forward the historical lease classifications. As such, we applied the modified retrospective approach as of the adoption date to those lease contracts for which we have taken possession of the property as of January 1, 2021. Results for reporting periods beginning on or after January 1, 2021 are presented under ASC 842. Upon transition, on January 1, 2021, we recorded the following increases (decreases) to the respective line items on the Consolidated Balance Sheet: (in thousands) Adjustment as of January 1, 2021 Operating lease ROU asset $ 28,044 Property, equipment and capitalized software, net (63) Short-term operating lease liabilities 5,118 Other current liabilities (1,231) Long-term operating lease liabilities 24,156 Accumulated deficit (17) Non-controlling interests (46) Nature of Leases Under ASC 842, we determine if an arrangement is a lease at inception of the arrangement. We have entered into operating and finance lease agreements with lease periods expiring between 2022 and 2032. Operating leases primarily consist of real estate and data centers, and finance leases primarily consist of office equipment. As of January 1, 2021, with the adoption of ASC 842, leases are included in operating lease right-of-use (“ROU”) assets and lease liabilities on our Condensed Consolidated Balance Sheets. Operating lease ROU assets and lease liabilities are recognized at the lease commencement date. Operating lease ROU assets represent our right to use an underlying asset and are based upon the lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. Lease liabilities represent the present value of lease payments over the lease term. The implicit rate within each lease is not readily determinable and therefore we use our incremental borrowing rate at the lease commencement date to determine the present value of the lease payments. The determination of the incremental borrowing rate requires judgement. We determined our incremental borrowing rate for each lease using indicative bank borrowing rates, adjusted for various factors including level of collateralization, term and treasury yield curves to align with the terms of the respective lease. The Company has elected the following practical expedients for all classes of leased assets: • Adopt the short-term lease exception for leases with terms of twelve months or less and account for them as if they were operating leases under ASC 840; and • Apply the practical expedient of combining lease and non-lease components. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. We do not include any renewal options in the lease terms for calculating lease liability, as the renewal options allow us to maintain operational flexibility and we are not reasonably certain that we will exercise these renewal options at the time of lease commencement. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term. Components of lease expense are as follows, all recorded within operating expenses in the Condensed Consolidated Statement of Operations: Three months ended Mar. 31, (in thousands) 2022 2021 Finance lease cost (1) $ 61 $ 85 Operating lease cost 1,947 1,796 Short-term lease cost (2) 83 119 Variable lease cost (3) 44 43 Sublease income (275) — Total net lease expense $ 1,860 $ 2,043 (1) Primarily consists of amortization of finance lease right-of-use assets and an immaterial amount of interest on finance lease liabilities recorded in operating expenses and interest expense in the condensed consolidated statements of operations. (2) Includes costs related to leases, which at the commencement date, have a lease term of 12 months or less. (3) Includes costs made by the Company for the right to use an underlying asset that vary because of changes in facts or circumstances occurring after the commencement date, other than the passage of time. On May 12, 2020, the Company entered into a lease agreement with Wilson Tech 5, LLC, for a proposed site in Lindon, Utah, beginning in 2022. The Company will not have access to the leased premises until construction is complete, the “commencement date,” and is not deemed to be the owner during the construction period. This lease agreement expires ten years after the commencement date. The Company did not make any lease payments during the three months ended March 31, 2022 and 2021 under this lease. The initial base annual rent will be approximately $4.6 million beginning in mid-2022. On February 15, 2022, the Company entered into a lease agreement for a site in Slovakia related to our Slovakian operations. The lease is expected to commence on October 1, 2022 with a lease term through March 31, 2030. As of March 31, 2022, future minimum lease payments for finance and operating leases consisted of the following: (in thousands) Finance Leases Operating Leases Remainder of 2022 $ 42 $ 5,666 2023 — 7,584 2024 — 6,406 2025 — 5,039 2026 — 1,929 Thereafter — 859 Total lease payments $ 42 $ 27,483 Less: Imputed interest — (3,049) Present value of lease liabilities $ 42 $ 24,434 Supplemental cash flow information related to leases are as follows: Three months ended Mar. 31, (in thousands) 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 1,832 $ 1,618 Operating cash flows from finance leases $ 1 $ 6 Financing cash flows from finance leases $ 62 $ 76 The weighted average remaining lease term and discount rate are as follows: Three months ended Mar. 31, (in thousands) 2022 2021 Weighted average remaining lease term (in years): Operating leases 3.9 years 4.9 years Finance leases 0.2 years 1.2 years Weighted average discount rate: Operating leases 6.2 % 6.1 % Finance leases 6.5 % 6.5 %

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Legal Proceedings In September 2020, three purported securities class action complaints were filed in the United States District Court for the Northern District of Illinois against the Company, certain of its officers and directors, and certain underwriters, private equity firms, and investment vehicles alleging violations of the Securities Act of 1933. On December 10, 2020, the court in the earliest filed action consolidated the three complaints, appointed lead plaintiffs and lead counsel for the consolidated action, and captioned the consolidated action “In re GoHealth, Inc. Securities Litigation”. Lead plaintiffs filed a consolidated complaint on February 25, 2021. The Company and officer and director defendants filed a responsive pleading on April 26, 2021 to dismiss the complaint. On April 5, 2022, that motion was denied. GoHealth’s current deadline to file an answer to the complaint is May 17, 2022. The parties have agreed to extend the answer deadline to May 31, 2022, which will be presented to the Court for approval. On May 19, 2021, a derivative action against certain of the Company’s officers and directors was filed, alleging substantially the same allegations as the In re GoHealth, Inc. Securities Litigation. The case was previously stayed while the motion to dismiss in the In re GoHealth, Inc. Securities Litigation was pending. The stay has now been lifted. The parties have until June 1, 2022 to file a joint status report. The Company disputes each claim in the above referenced matters and intends to defend the pending actions noted above. It is too early for GoHealth to provide any reliable assessment of the likely quantum of any damages that may become payable if its defense is unsuccessful in whole or in part. While GoHealth feels confident in its defense of these pending matters, there can be no assurance that it will prevail and that any damages that may be awarded will not be material to the results of operations or financial condition of GoHealth.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	RELATED PARTY TRANSACTIONS The Company is party to various lease agreements with 214 W Huron LLC, 220 W Huron Street Holdings LLC, and 215 W Superior LLC, each of which are controlled by significant shareholders of the Company, to lease its corporate offices in Chicago, Illinois. The Company pays rent, operating expenses, maintenance, and utilities under the terms of the leases. For both the three months ended March 31, 2022 and 2021, the Company made aggregate lease payments of $0.3 million under these leases. On January 1, 2020, the Company entered into a non-exclusive aircraft dry lease agreement with an entity wholly-owned and controlled by certain significant shareholders of the Company. The agreement allows the Company to use an aircraft owned by this entity for business and on an as-needed basis. The agreement has no set term and is terminable without cause by either party upon 30 days’ prior written notice. Under the agreement, the Company is required to pay $6,036.94 per flight hour for use of the aircraft. For the three months ended March 31, 2022 and 2021, the Company recorded expense of $0.4 million and $0.1 million, respectively, under this lease. As discussed in Footnote 10 “Leases”, on May 12, 2020, the Company entered into a lease agreement with Wilson Tech 5, LLC, which is controlled by significant shareholders of the Company, for a proposed site in Lindon, Utah, beginning in 2022. This lease has not commenced as of March 31, 2022. During the twelve months ended December 31, 2020, the Company provided a short-term advancement to NVX Holdings, Inc., which is controlled by significant shareholders of the Company, for which the Company recorded a receivable of $3.4 million. The advancement was collected by the Company during the three months ended March 31, 2021.

Operating Segments and Signific

Operating Segments and Significant Customers	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Operating Segments and Significant Customers	OPERATING SEGMENTS AND SIGNIFICANT CUSTOMERS Operating Segments The Company reports segment information based on how the Company’s chief operating decision maker (“CODM”) regularly reviews operating results, allocates resources and makes decisions regarding business operations. The performance measures of the segments include total revenue and profit (loss). For segment reporting purposes in accordance with ASC 280-10, Segment Reporting , the Company’s business structure is comprised of four operating and reportable segments: Medicare Internal and External: The Medicare internal and external segments consist primarily of revenues earned from sales of Medicare Advantage, Medicare Supplement, Prescription Drug Plans, and Medicare Special Needs Plans (or “SNPs”), for multiple carriers. Individual and Family Plan and Other (“IFP and Other”) Internal and External: The IFP and Other internal and external segments consist primarily of revenues earned from sales of individual and family plans, dental plans, vision plans and other ancillary plans to individuals that are not Medicare-eligible. The Internal and External segments relative to both Medicare and IFP are defined as follows: Internal: The two internal segments primarily consist of sales of products and plans by Company-employed agents offering qualified prospects plans from multiple carriers, Company-employed agents offering qualified prospects plans on a carrier-specific basis, or sales of products and plans through our online platform without the assistance of our agents (do-it-yourself or “DIY”). The Company earns revenue in this channel through commissions paid by carriers based on sales the Company generates, as well as enrollment fees, hourly fees and other fees for services performed for specific carriers and other partners. External: The two external segments represent sales of products and plans under the Company’s carrier contracts using an independent, national network of agents who are not employed by the Company. These agents utilize the Company’s technology and platform to enroll consumers in health insurance plans and provide a means to earn a return on leads that otherwise may have not been addressed. The Company also sells insurance prospects (or “leads”) to agencies within this channel. The Company earns revenue in this channel through commissions paid by carriers as a result of policy sales, as well as sales of leads to external agencies. The following table presents summary results of the Company’s operating segments for the periods indicated: Three months ended Mar. 31, (in thousands) 2022 2021 Net revenues: Medicare: Internal channel $ 203,845 $ 157,353 External channel 61,486 39,500 Total Medicare 265,331 196,853 IFP and Other: Internal channel 4,200 3,975 External channel 1,062 3,351 Total IFP and Other 5,262 7,326 Net revenues 270,593 204,179 Segment profit (loss): Medicare: Internal channel 34,839 46,443 External channel (7,793) (631) Total Medicare 27,046 45,812 IFP and Other: Internal channel 590 (729) External channel (258) 160 Total IFP and Other 332 (569) Segment profit (loss) 27,378 45,243 Corporate expense 29,172 20,319 Amortization of intangible assets 23,514 23,514 Interest expense 11,398 8,688 Other (income) expense, net 63 13 Income (loss) before income taxes $ (36,769) $ (7,291) There are no internal revenue transactions between the Company’s operating segments. Substantially all revenue for the periods presented was generated from customers located in the United States. The Company’s CODM does not separately evaluate assets by segment, and therefore assets by segment are not presented. The Company’s assets are primarily located in the United States. Significant Customers The following table presents carriers representing 10% or more of the Company’s total revenue for the periods indicated: Three months ended Mar. 31, 2022 2021 Anthem 25 % 30 % Humana 24 % 28 % United 18 % 18 % Centene 15 % 16 % Aetna 10 % 1 % Substantially all of the revenue from these customers was from the sales of products and plans within the Medicare—Internal and Medicare—External segments. Concentration of Credit Risk The Company does not require collateral or other security in granting credit. As of March 31, 2022, three customers each represented 10% or more of the Company’s total accounts receivable and unbilled receivables and, in aggregate, represented 80%, or $36.8 million, of the combined total. As of December 31, 2021, three customers each represented 10% or more of the Company’s total accounts receivable and unbilled receivables and, in aggregate, represented 87%, or $28.7 million, of the combined total.

Description of Business and S_2

Description of Business and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies In connection with the IPO, the Company became the sole managing member of GHH, LLC and controls the management of GHH, LLC. As a result, the Company consolidates GHH, LLC’s financial results in its Condensed Consolidated Financial Statements and reports a non-controlling interest for the economic interest in GHH, LLC held by the Continuing Equity Owners. Substantially concurrently with the consummation of the IPO, the existing limited liability company agreement of GHH, LLC was amended and restated to, among other things, recapitalize its capital structure by creating a single new class of units (the “common units”) and provide for a right of redemption of common units (subject in certain circumstances to time-based vesting requirements and certain other restrictions) in exchange for, at the Company’s election, cash or newly-issued shares of Class A common stock on a one-for-one basis. In connection with any redemption, the Company will receive a corresponding number of common units, increasing the Company’s total ownership interest in GHH, LLC. Net income and loss is allocated to the Continuing Equity Owners on a pro rata basis, assuming that any Class B common units that are subject to time-based vesting requirements are fully vested. GHH, LLC is a holding company with no operating assets or operations and was formed to acquire a 100% equity interest in Norvax, LLC (“Norvax”). On May 6, 2020, Blizzard Parent, LLC changed its name to GoHealth Holdings, LLC. GHH, LLC owns 100% of Blizzard Midco, LLC, which owns 100% of Norvax. For all of the periods reported in these Condensed Consolidated Financial Statements, GHH, LLC has not and does not have any material operations on a standalone basis, and all of the operations of GHH, LLC are carried out by Norvax. The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, but do not include all information and footnote disclosures required under GAAP for annual financial statements. In the opinion of management, the interim Condensed Consolidated Financial Statements include all adjustments, consisting only of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position, results of operations and cash flows as of the dates and for the periods presented. All intercompany transactions and balances are eliminated in consolidation. Certain prior period amounts have been reclassified to conform with the current period presentation. Effective on December 31, 2021, we lost our emerging growth company ("EGC") status, which accelerated the adoption of Accounting Standards Update (“ASU”) 2016-02, Leases and ASU 2019-11, Financial Instruments – Credit Losses . As a result, we recast our previously reported consolidated financial statements effective January 1, 2021 to reflect the adoption of these standards.
Use of Estimates	Use of Estimates The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities at the date of the Condensed Consolidated Financial Statements, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets
Seasonality	Seasonality A greater number of the Company’s Medicare-related health insurance plans are sold in its fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, the Company’s Medicare plan-related commission revenue is typically highest in the Company’s fourth quarter. The majority of the Company’s individual and family health insurance plans are sold in its fourth quarter during the annual open enrollment period as defined under the federal Patient Protection and ACA and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase individual and family health insurance outside of the open enrollment period, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state. As a result, the Company’s individual and family plan-related commission revenue is typically highest in the Company’s fourth quarter.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842). The guidance specifies that lessees will need to recognize a right-of-use asset and a lease liability for virtually all their leases except those which meet the definition of a short-term lease. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or financing. Classification will be based on criteria that are similar to those applied in current lease accounting, but without explicit bright lines. The Company adopted the new guidance effective January 1, 2021. The Company elected the optional transition method which allows entities to continue to apply historical accounting guidance in the comparative periods presented in the year of adoption. At transition, lessees and lessors may elect to apply a package of practical expedients permitting entities not to reassess: (i) whether any expired or existing contracts are or contain leases; (ii) lease classification for any expired or existing leases and (iii) whether initial direct costs for any expired or existing leases qualify for capitalization under the amended guidance. These practical expedients must be elected as a package and consistently applied. The Company applied the package of practical expedients upon adoption. As a result of adopting this standard, on January 1, 2021, the Company recorded lease liabilities of $29.3 million, right-of-use assets of $28.0 million, and an immaterial cumulative catch-up adjustment to opening equity. The adoption of this new standard did not have a material impact on the Company’s consolidated statements of operations, comprehensive income (loss), or cash flows. The Company has included expanded disclosures on the condensed consolidated balance sheets and in Note 10 to the Condensed Consolidated Financial Statements. In November 2019, the FASB issued ASU 2019-11, Financial Instruments – Credit Losses
Revenue Recognition for Variable Consideration	Revenue Recognition for Variable Consideration The Company’s variable consideration includes the total estimated lifetime value (“LTV”) it expects to receive for selling an insurance product after the carrier approves an application. The consideration is variable based on the amount of time it estimates a policy will remain in force, which is based on historical experience or carrier experience to the extent available, industry data, and expectations as to future retention rates. Additionally, the Company considers the application of a constraint and only recognizes the amount of variable consideration that it believes is probable that it will be entitled to receive and will not be subject to a significant revenue reversal in the future. Due to lower persistency observed during the three months ended March 31, 2022 and declining LTV estimates, the Company applied an incremental LTV constraint to all Medicare policies sold in the first quarter of 2022.

Goodwill And Intangible Asset_2

Goodwill And Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Definite-lived Amortizable Intangible Assets	The gross carrying amounts, accumulated amortization and net carrying amounts of the Company’s definite-lived amortizable intangible assets, as well as its indefinite-lived intangible trade names, are as follows: Mar. 31, 2022 (in thousands) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 496,000 $ 180,686 $ 315,314 Customer relationships 232,000 59,160 172,840 Total intangible assets subject to amortization $ 728,000 $ 239,846 $ 488,154 Indefinite-lived trade names 83,000 Total intangible assets $ 571,154 Dec. 31, 2021 (in thousands) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 496,000 $ 162,971 $ 333,029 Customer relationships 232,000 53,360 178,640 Total intangible assets subject to amortization $ 728,000 $ 216,331 $ 511,669 Indefinite-lived trade names 83,000 Total intangible assets $ 594,669
Schedule of Indefinite-lived Intangible Trade Names	The gross carrying amounts, accumulated amortization and net carrying amounts of the Company’s definite-lived amortizable intangible assets, as well as its indefinite-lived intangible trade names, are as follows: Mar. 31, 2022 (in thousands) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 496,000 $ 180,686 $ 315,314 Customer relationships 232,000 59,160 172,840 Total intangible assets subject to amortization $ 728,000 $ 239,846 $ 488,154 Indefinite-lived trade names 83,000 Total intangible assets $ 571,154 Dec. 31, 2021 (in thousands) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 496,000 $ 162,971 $ 333,029 Customer relationships 232,000 53,360 178,640 Total intangible assets subject to amortization $ 728,000 $ 216,331 $ 511,669 Indefinite-lived trade names 83,000 Total intangible assets $ 594,669
Schedule of Expected Amortization Expense Related to Intangible Assets	As of March 31, 2022, expected amortization expense related to intangible assets for each of the five succeeding years is as follows: (in thousands) Developed Technology Customer Relationships Total Remainder of 2022 $ 53,143 $ 17,400 $ 70,543 2023 70,857 23,200 94,057 2024 70,857 23,200 94,057 2025 70,857 23,200 94,057 2026 49,600 23,200 72,800 Thereafter — 62,640 62,640 Total $ 315,314 $ 172,840 $ 488,154

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Summary of Long-Term Debt	The Company’s long-term debt consisted of the following: (in thousands) Mar. 31, 2022 Dec. 31, 2021 Term Loan Facilities $ 522,085 $ 523,403 Revolving Credit Facilities 155,000 155,000 Less: Unamortized debt discount and issuance costs (9,137) (8,018) Total debt $ 667,948 $ 670,385 Less: Current portion of long-term debt (5,270) (5,270) Total long-term debt $ 662,678 $ 665,115

Share-Based Compensation Plans

Share-Based Compensation Plans (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Summary of Share-Based Compensation Expenses by Operating Function	The following table summarizes share-based compensation expense by operating function for the periods presented: Three months ended Mar. 31, (in thousands) 2022 2021 Marketing and advertising $ 441 $ 337 Customer care and enrollment 631 796 Technology 982 747 General and administrative 3,101 3,232 Total share-based compensation expense $ 5,155 $ 5,112

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Summary of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss Per Share	A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows: Three months ended Mar. 31, (in thousands, except per share amounts) 2022 2021 Numerator: Net loss $ (37,241) $ (7,260) Less: Net loss attributable to non-controlling interests (23,758) (5,173) Net loss attributable to GoHealth, Inc. (13,483) (2,087) Denominator: Weighted-average shares of Class A common stock outstanding—basic 116,207 92,343 Effect of dilutive securities — — Weighted-average shares of Class A common stock outstanding—diluted 116,207 92,343 Net loss per share of Class A common stock—basic and diluted $ (0.12) $ (0.02)
Schedule of Antidilutive Securities Excluded From Calculation of Diluted Loss Per Share	The following number of shares were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive: Mar. 31, (in thousands) 2022 2021 Class A common stock issuable pursuant to equity awards 6,375 6,539 Class B common stock 199,338 222,606

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Summary of Disaggregation of Revenue	The table below depicts the disaggregation of revenue by product, and is consistent with how the Company evaluates its financial performance: Three months ended Mar. 31, (in thousands) 2022 2021 Commission revenue: Medicare: Medicare Advantage $ 206,634 $ 168,148 Medicare Supplement 312 784 Prescription Drug Plans 1,254 553 Total Medicare 208,200 169,485 Individual and Family Plan: Fixed Indemnity 381 2,781 Short-term 171 400 Major Medical 72 201 Total Individual and Family Plan 624 3,382 Ancillary 811 1,108 Small Group 4 6 Total commission revenue 209,639 173,981 Enterprise revenue: Partner Marketing and Enrollment Services 40,664 21,857 Direct Partner Campaigns 20,116 8,102 Other 174 239 Total enterprise revenue 60,954 30,198 Net revenues $ 270,593 $ 204,179
Summary of Commissions Receivable Activity	Commissions receivable activity is summarized as follows: Three months ended Mar. 31, (in thousands) 2022 2021 Beginning balance $ 1,262,507 $ 809,859 Commission revenue 209,639 173,981 Cash receipts (335,663) (183,489) Allowance for credit loss 84 6 Ending balance $ 1,136,567 $ 800,357 Less: Commissions receivable - current 189,287 98,157 Commissions receivable - non-current $ 947,280 $ 702,200

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Schedule of Impact of Adoption of ASU 2016-02	Upon transition, on January 1, 2021, we recorded the following increases (decreases) to the respective line items on the Consolidated Balance Sheet: (in thousands) Adjustment as of January 1, 2021 Operating lease ROU asset $ 28,044 Property, equipment and capitalized software, net (63) Short-term operating lease liabilities 5,118 Other current liabilities (1,231) Long-term operating lease liabilities 24,156 Accumulated deficit (17) Non-controlling interests (46)
Components of Lease Expense, Supplemental Cash Flow Information and Weighted Average Remaining Lease Term and Discount Rate	Components of lease expense are as follows, all recorded within operating expenses in the Condensed Consolidated Statement of Operations: Three months ended Mar. 31, (in thousands) 2022 2021 Finance lease cost (1) $ 61 $ 85 Operating lease cost 1,947 1,796 Short-term lease cost (2) 83 119 Variable lease cost (3) 44 43 Sublease income (275) — Total net lease expense $ 1,860 $ 2,043 (1) Primarily consists of amortization of finance lease right-of-use assets and an immaterial amount of interest on finance lease liabilities recorded in operating expenses and interest expense in the condensed consolidated statements of operations. (2) Includes costs related to leases, which at the commencement date, have a lease term of 12 months or less. (3) Includes costs made by the Company for the right to use an underlying asset that vary because of changes in facts or circumstances occurring after the commencement date, other than the passage of time. Supplemental cash flow information related to leases are as follows: Three months ended Mar. 31, (in thousands) 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 1,832 $ 1,618 Operating cash flows from finance leases $ 1 $ 6 Financing cash flows from finance leases $ 62 $ 76 The weighted average remaining lease term and discount rate are as follows: Three months ended Mar. 31, (in thousands) 2022 2021 Weighted average remaining lease term (in years): Operating leases 3.9 years 4.9 years Finance leases 0.2 years 1.2 years Weighted average discount rate: Operating leases 6.2 % 6.1 % Finance leases 6.5 % 6.5 %
Schedule of Future Minimum Payments for Finance Leases	As of March 31, 2022, future minimum lease payments for finance and operating leases consisted of the following: (in thousands) Finance Leases Operating Leases Remainder of 2022 $ 42 $ 5,666 2023 — 7,584 2024 — 6,406 2025 — 5,039 2026 — 1,929 Thereafter — 859 Total lease payments $ 42 $ 27,483 Less: Imputed interest — (3,049) Present value of lease liabilities $ 42 $ 24,434
Schedule of Future Minimum Payments for Operating Leases	As of March 31, 2022, future minimum lease payments for finance and operating leases consisted of the following: (in thousands) Finance Leases Operating Leases Remainder of 2022 $ 42 $ 5,666 2023 — 7,584 2024 — 6,406 2025 — 5,039 2026 — 1,929 Thereafter — 859 Total lease payments $ 42 $ 27,483 Less: Imputed interest — (3,049) Present value of lease liabilities $ 42 $ 24,434

Operating Segments and Signif_2

Operating Segments and Significant Customers (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Summary of Reconciliation of Operating Profit (Loss) From Segments to Consolidated	The following table presents summary results of the Company’s operating segments for the periods indicated: Three months ended Mar. 31, (in thousands) 2022 2021 Net revenues: Medicare: Internal channel $ 203,845 $ 157,353 External channel 61,486 39,500 Total Medicare 265,331 196,853 IFP and Other: Internal channel 4,200 3,975 External channel 1,062 3,351 Total IFP and Other 5,262 7,326 Net revenues 270,593 204,179 Segment profit (loss): Medicare: Internal channel 34,839 46,443 External channel (7,793) (631) Total Medicare 27,046 45,812 IFP and Other: Internal channel 590 (729) External channel (258) 160 Total IFP and Other 332 (569) Segment profit (loss) 27,378 45,243 Corporate expense 29,172 20,319 Amortization of intangible assets 23,514 23,514 Interest expense 11,398 8,688 Other (income) expense, net 63 13 Income (loss) before income taxes $ (36,769) $ (7,291)
Summary of Revenue by Major Customers by Reporting Segments	The following table presents carriers representing 10% or more of the Company’s total revenue for the periods indicated: Three months ended Mar. 31, 2022 2021 Anthem 25 % 30 % Humana 24 % 28 % United 18 % 18 % Centene 15 % 16 % Aetna 10 % 1 %

Description of Business and S_3

Description of Business and Significant Accounting Policies - Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)	May 06, 2020
Class of Stock [Line Items]
Common units to class A common stock, conversion ratio	1
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Lease liabilities	$ 24,434
Right-of-use assets	22,044	$ 23,462
Total stockholders’ equity	$ (859,958)	$ (892,490)	$ (1,396,412)	$ (1,399,155)
GHH, LLC | Norvax
Class of Stock [Line Items]
Equity method investment ownership percentage	100.00%
GHH, LLC | Blizzard Midco
Class of Stock [Line Items]
Equity method investment ownership percentage					100.00%
Blizzard Midco | Norvax
Class of Stock [Line Items]
Equity method investment ownership percentage					100.00%
Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Lease liabilities				29,300
Right-of-use assets				28,044
Cumulative Effect, Period of Adoption, Adjustment | Cumulative impact of Topic 326
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total stockholders’ equity				$ 539

Goodwill And Intangible Asset_3

Goodwill And Intangible Assets, Net - Narrative (Details)	3 Months Ended			12 Months Ended
	Mar. 31, 2022USD ($)reporting_unitsegment	Dec. 31, 2021USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2019USD ($)
Goodwill [Line Items]
Number of reporting units | reporting_unit	4
Number of operating segments | segment	4
Impairment of goodwill			$ 0
Impairment of intangible assets	$ 0		$ 0
Medicare-Internal Reporting Unit
Goodwill [Line Items]
Impairment of goodwill		$ 380,300,000
Medicare-External Reporting Unit
Goodwill [Line Items]
Impairment of goodwill		$ 6,200,000
Medicare—Internal
Goodwill [Line Items]
Goodwill recorded				$ 380,300,000
Medicare—External
Goodwill [Line Items]
Goodwill recorded				$ 6,200,000

Goodwill And Intangible Asset_4

Goodwill And Intangible Assets, Net - Summary of Definite-lived and Indefinite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 728,000	$ 728,000
Accumulated Amortization	239,846	216,331
Net Carrying Amount	488,154	511,669
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Net Carrying Amount	571,154	594,669
Indefinite-lived trade names
Indefinite-lived Intangible Assets [Line Items]
Net Carrying Amount	83,000	83,000
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	496,000	496,000
Accumulated Amortization	180,686	162,971
Net Carrying Amount	315,314	333,029
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	232,000	232,000
Accumulated Amortization	59,160	53,360
Net Carrying Amount	$ 172,840	$ 178,640

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net - Summary of Expected Future Amortization Expense Related to Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Remainder of 2022	$ 70,543
2023	94,057
2024	94,057
2025	94,057
2026	72,800
Thereafter	62,640
Net Carrying Amount	488,154	$ 511,669
Developed technology
Finite-Lived Intangible Assets [Line Items]
Remainder of 2022	53,143
2023	70,857
2024	70,857
2025	70,857
2026	49,600
Thereafter	0
Net Carrying Amount	315,314	333,029
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Remainder of 2022	17,400
2023	23,200
2024	23,200
2025	23,200
2026	23,200
Thereafter	62,640
Net Carrying Amount	$ 172,840	$ 178,640

Long-Term Debt - Summary of Lon

Long-Term Debt - Summary of Long-Term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Less: Unamortized debt discount and issuance costs	$ (9,137)	$ (8,018)
Total debt	667,948	670,385
Less: Current portion of long-term debt	(5,270)	(5,270)
Total long-term debt	662,678	665,115
Term Loan Facilities
Debt Instrument [Line Items]
Long-term debt gross	522,085	523,403
Revolving Credit Facilities
Debt Instrument [Line Items]
Long-term debt gross	$ 155,000	$ 155,000

Long-Term Debt - Narrative (Det

Long-Term Debt - Narrative (Details) - USD ($)	Mar. 14, 2022	Nov. 10, 2021	Jun. 11, 2021	Mar. 31, 2022	Dec. 31, 2021	May 07, 2021	Dec. 31, 2020	Sep. 13, 2019
Term Loan Facilities
Debt Instrument [Line Items]
Debt issuance costs	$ 1,700,000
Periodic payment percentage				0.25%
Term Loan Facilities | Initial Term Loan Facility
Debt Instrument [Line Items]
Amount outstanding			$ 295,500,000					$ 300,000,000
Loss on extinguishment of debt			$ 11,900,000
Prepayment premium, percentage			2.00%
Prepayment premium			$ 5,900,000
Write-down of deferred financing costs and debt discounts			6,000,000
Term Loan Facilities | Incremental Term Loan Facility
Debt Instrument [Line Items]
Aggregate principal amount							$ 117,000,000
Amount outstanding				$ 114,700,000	$ 115,000,000
Effective interest rate				7.50%	7.50%
Term Loan Facilities | Incremental Term Loan Facility | Alternate Base Rate
Debt Instrument [Line Items]
Variable interest rate spread				5.50%
Term Loan Facilities | Incremental Term Loan Facility | LIBOR
Debt Instrument [Line Items]
Variable interest rate spread				6.50%
Term Loan Facilities | 2021 Incremental Term Loan Facility
Debt Instrument [Line Items]
Aggregate principal amount			310,000,000
Amount outstanding				$ 307,700,000	$ 308,400,000
Debt issuance costs			1,700,000
Effective interest rate				7.50%	6.00%
Term Loan Facilities | 2021 Incremental Term Loan Facility | Alternate Base Rate
Debt Instrument [Line Items]
Variable interest rate spread	5.50%	4.00%
Term Loan Facilities | 2021 Incremental Term Loan Facility | LIBOR
Debt Instrument [Line Items]
Variable interest rate spread	6.50%	5.00%
Term Loan Facilities | 2021-2 Incremental Term Loan Facility
Debt Instrument [Line Items]
Aggregate principal amount		$ 100,000,000
Amount outstanding				$ 99,700,000	$ 100,000,000
Debt issuance costs		$ 2,500,000
Effective interest rate				7.50%	6.00%
Term Loan Facilities | 2021-2 Incremental Term Loan Facility | Alternate Base Rate
Debt Instrument [Line Items]
Variable interest rate spread	5.50%	4.00%
Term Loan Facilities | 2021-2 Incremental Term Loan Facility | LIBOR
Debt Instrument [Line Items]
Variable interest rate spread	6.50%	5.00%
Revolving Credit Facilities
Debt Instrument [Line Items]
Aggregate principal amount						$ 200,000,000
Commitment fee percentage				0.50%
Remaining borrowing capacity				$ 45,000,000
Revolving Credit Facilities | Revolving Credit Facility
Debt Instrument [Line Items]
Aggregate principal amount								$ 30,000,000
Revolving Credit Facilities | Incremental Revolving Credit Facilities
Debt Instrument [Line Items]
Aggregate principal amount							$ 28,000,000
Revolving Credit Facilities | Incremental No. 4 Revolving Credit Facility
Debt Instrument [Line Items]
Aggregate principal amount						$ 142,000,000
Revolving Credit Facilities | Class A Revolving Commitments
Debt Instrument [Line Items]
Aggregate principal amount			30,000,000
Amount outstanding				$ 23,200,000	$ 23,200,000
Effective interest rate				7.50%	7.50%
Revolving Credit Facilities | Class A Revolving Commitments | Alternate Base Rate
Debt Instrument [Line Items]
Variable interest rate spread				5.50%
Revolving Credit Facilities | Class A Revolving Commitments | LIBOR
Debt Instrument [Line Items]
Variable interest rate spread				6.50%
Revolving Credit Facilities | Class B Revolving Commitments
Debt Instrument [Line Items]
Aggregate principal amount			$ 170,000,000
Amount outstanding				$ 131,800,000	$ 131,800,000
Effective interest rate				5.00%	5.00%
Revolving Credit Facilities | Class B Revolving Commitments | Alternate Base Rate
Debt Instrument [Line Items]
Variable interest rate spread				3.00%
Revolving Credit Facilities | Class B Revolving Commitments | LIBOR
Debt Instrument [Line Items]
Variable interest rate spread				4.00%

Stockholders' Equity and Memb_2

Stockholders' Equity and Members' Equity (Details) shares in Thousands	1 Months Ended	3 Months Ended
	Jul. 31, 2020vote$ / sharesshares	Mar. 31, 2022$ / sharesshares	Mar. 31, 2021	Dec. 31, 2021$ / sharesshares
Class of Stock [Line Items]
Preferred stock, shares authorized (in shares) | shares	20,000	20,000		20,000
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001	$ 0.0001		$ 0.0001
Ratio between the number of shares of Class A common stock issued and the number of LLC Interests owned	1
GHH, LLC
Class of Stock [Line Items]
Weighted-average ownership percentage by non-controlling interest holders		63.80%	71.20%
Continuing Equity Owners and permitted transferees
Class of Stock [Line Items]
Ratio between the number of shares of Class B common stock owned and the number of LLC Interests owned	1
GHH, LLC
Class of Stock [Line Items]
LLC Interests to newly issued Class A common stock, conversion ratio	1
Class A Common Stock
Class of Stock [Line Items]
Common stock, shares authorized (in shares) | shares	1,100,000	1,100,000		1,100,000
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001	$ 0.0001		$ 0.0001
Number of votes per common share held | vote	1
Class B common stock
Class of Stock [Line Items]
Common stock, shares authorized (in shares) | shares	690,000	581,346		587,360
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001	$ 0.0001		$ 0.0001
Number of votes per common share held | vote	1

Share-Based Compensation Plan_2

Share-Based Compensation Plans - Summary of Share-Based Compensation Expenses by Operating Function (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 5,155	$ 5,112
Marketing and advertising
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	441	337
Customer care and enrollment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	631	796
Technology
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	982	747
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 3,101	$ 3,232

Share-Based Compensation Plan_3

Share-Based Compensation Plans - Narrative (Details) $ / shares in Units, $ in Thousands	Apr. 25, 2022d$ / shares	Jul. 07, 2020	Mar. 31, 2022USD ($)$ / sharesshares	Mar. 31, 2021USD ($)shares	Dec. 19, 2021shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $			$ 5,155	$ 5,112
Subsequent event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Trailing trading days for closing price | d	20
Subsequent event | Prior to April 1, 2022 | Employees, excluding certain Executive Officers
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding stock options exercise price (in dollars per share) | $ / shares	$ 1.05
PSU's
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted (in shares) | shares			489,000
Performance period			3 years
Risk-free interest rate			0.20%
Annualized volatility			72.00%
Grant date fair value (in dollars per share) | $ / shares			$ 22.17
Share-based compensation expense | $			$ 900	500
PSU's | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target award			0.00%
PSU's | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target award			200.00%
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $			$ 200	$ 100
ESPP purchase price of common stock, percent of market price		85.00%
Share-based compensation arrangement by share-based payment award, shares issued in period (in shares) | shares			0	0
2021 Employment Inducement Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance (in shares) | shares					4,000,000

Net Loss Per Share - Reconcilia

Net Loss Per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net loss	$ (37,241)	$ (7,260)
Less: Net loss attributable to non-controlling interests	(23,758)	(5,173)
Net income (loss) attributable to GoHealth, Inc.	$ (13,483)	$ (2,087)
Denominator:
Weighted-average shares of Class A common stock outstanding — basic (in shares)	116,207	92,343
Effect of dilutive securities (in shares)	0	0
Weighted-average shares of Class A common stock outstanding—diluted	116,207	92,343
Net loss per share of Class A common stock — basic (in dollars per share)	$ (0.12)	$ (0.02)
Net loss per share of Class A common stock — diluted (in dollars per share)	$ (0.12)	$ (0.02)

Net Loss Per Share - Antidiluti

Net Loss Per Share - Antidilutive Securities (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Class A common stock issuable pursuant to equity awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average potentially dilutive shares excluded from calculation of diluted loss per share because effect would be antidilutive (in shares)	6,375	6,539
Class B common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average potentially dilutive shares excluded from calculation of diluted loss per share because effect would be antidilutive (in shares)	199,338	222,606

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jul. 17, 2020
Income Tax Disclosure [Abstract]
Effective tax rate	(1.28%)	0.43%
Tax Receivable Agreement, payment, percent of amount of tax benefits realized or deemed to realize			85.00%
Tax Receivable Agreement, liability	$ 0

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Negative revenue adjustments relating to performance obligations satisfied in prior periods	$ 2.6	$ 2.2
Revenue recognized that was previously deferred	0.1	$ 0.1
Prepaid expenses and other current assets
Disaggregation of Revenue [Line Items]
Unbilled receivables for performance-based enrollment fees	$ 5.5		$ 20.1

Revenue - Summary of Disaggrega

Revenue - Summary of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Net revenues	$ 270,593	$ 204,179
Commission
Disaggregation of Revenue [Line Items]
Net revenues	209,639	173,981
Ancillary
Disaggregation of Revenue [Line Items]
Net revenues	811	1,108
Small Group
Disaggregation of Revenue [Line Items]
Net revenues	4	6
Enterprise
Disaggregation of Revenue [Line Items]
Net revenues	60,954	30,198
Partner Marketing and Enrollment Services
Disaggregation of Revenue [Line Items]
Net revenues	40,664	21,857
Direct Partner Campaigns
Disaggregation of Revenue [Line Items]
Net revenues	20,116	8,102
Other
Disaggregation of Revenue [Line Items]
Net revenues	174	239
Medicare
Disaggregation of Revenue [Line Items]
Net revenues	208,200	169,485
Medicare | Medicare Advantage
Disaggregation of Revenue [Line Items]
Net revenues	206,634	168,148
Medicare | Medicare Supplement
Disaggregation of Revenue [Line Items]
Net revenues	312	784
Medicare | Prescription Drug Plans
Disaggregation of Revenue [Line Items]
Net revenues	1,254	553
Individual and Family Plan
Disaggregation of Revenue [Line Items]
Net revenues	624	3,382
Individual and Family Plan | Fixed Indemnity
Disaggregation of Revenue [Line Items]
Net revenues	381	2,781
Individual and Family Plan | Short-term
Disaggregation of Revenue [Line Items]
Net revenues	171	400
Individual and Family Plan | Major Medical
Disaggregation of Revenue [Line Items]
Net revenues	$ 72	$ 201

Revenue - Summary of Commission

Revenue - Summary of Commissions Receivable Activity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Contract with Customer, Asset [Roll Forward]
Commission revenue	$ 270,593	$ 204,179
Less: Commissions receivable - current	189,287		$ 268,663
Commissions receivable - non-current	947,280		$ 993,844
Commission
Contract with Customer, Asset [Roll Forward]
Beginning balance	1,262,507	809,859
Commission revenue	209,639	173,981
Cash receipts	(335,663)	(183,489)
Allowance for credit loss	84	6
Ending balance	1,136,567	800,357
Less: Commissions receivable - current	189,287	98,157
Commissions receivable - non-current	$ 947,280	$ 702,200

Leases - Impact of Adoption of

Leases - Impact of Adoption of ASU 2016-02 (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease ROU asset	$ 22,044	$ 23,462
Property, equipment, and capitalized software, net	27,863	24,273
Short-term operating lease liabilities	6,249	6,126
Other current liabilities	11,067	8,344
Long-term operating lease liabilities	18,185	19,776
Accumulated deficit	(221,800)	(208,317)
Non-controlling interests	$ 498,833	$ 539,387
Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease ROU asset			$ 28,044
Property, equipment, and capitalized software, net			(63)
Short-term operating lease liabilities			5,118
Other current liabilities			(1,231)
Long-term operating lease liabilities			24,156
Accumulated deficit			(17)
Non-controlling interests			$ (46)

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Finance lease cost	$ 61	$ 85
Operating lease cost	1,947	1,796
Short-term lease cost	83	119
Variable lease cost	44	43
Sublease income	(275)	0
Total net lease expense	$ 1,860	$ 2,043

Leases - Narrative (Details)

Leases - Narrative (Details) - Affiliated Entity $ in Millions	May 12, 2020USD ($)
Related Party Transaction [Line Items]
Term of contract for lease not yet commenced	10 years
Initial annual base rent for lease not yet commenced	$ 4.6

Leases - Minimum Future Payment

Leases - Minimum Future Payments for Finance and Operating Leases (Details) $ in Thousands	Mar. 31, 2022USD ($)
Finance Leases
Remainder of 2022	$ 42
2023	0
2024	0
2025	0
2026	0
Thereafter	0
Total lease payments	42
Less: Imputed interest	0
Present value of lease liabilities	42
Operating Leases
Remainder of 2022	5,666
2023	7,584
2024	6,406
2025	5,039
2026	1,929
Thereafter	859
Total lease payments	27,483
Less: Imputed interest	(3,049)
Present value of lease liabilities	$ 24,434

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 1,832	$ 1,618
Operating cash flows from finance leases	1	6
Financing cash flows from finance leases	$ 62	$ 76

Leases - Weighted Average Remai

Leases - Weighted Average Remaining Lease Term and Discount Rate (Details)	Mar. 31, 2022	Mar. 31, 2021
Weighted average remaining lease term (in years):
Operating leases	3 years 10 months 24 days	4 years 10 months 24 days
Finance leases	2 months 12 days	1 year 2 months 12 days
Weighted average discount rate:
Operating leases	6.20%	6.10%
Finance leases	6.50%	6.50%

Commitments and Contingencies (

Commitments and Contingencies (Details)	1 Months Ended
	Sep. 30, 2020claim
Pending litigation
Loss Contingencies [Line Items]
Number of securities class action complaints filed	3

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Lease payments	$ 300,000	$ 300,000
Receivable from NVX Holdings, Inc.			$ 3,400,000
Non-Exclusive Aircraft Dry Lease Agreement
Related Party Transaction [Line Items]
Agreement terminable without cause by either party, period of required prior written notice	30 days
Amount required to pay per flight hour for use of aircraft	$ 6,036.94
Lease expenses incurred	$ 400,000	$ 100,000

Operating Segments and Signif_3

Operating Segments and Significant Customers - Narrative (Details) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2022USD ($)segment	Dec. 31, 2021USD ($)
Segment Reporting [Abstract]
Number of operating segments	4
Number of reportable segments	4
Three customers | Accounts receivable and unbilled receivables | Customer concentration risk
Revenue, Major Customer [Line Items]
Concentration risk, percentage	80.00%	87.00%
Accounts receivable and unbilled receivables | $	$ 36.8	$ 28.7

Operating Segments and Signif_4

Operating Segments and Significant Customers - Summary of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net revenues:
Net revenues	$ 270,593	$ 204,179
Segment profit (loss):
Segment profit (loss)	(25,308)	1,410
Corporate expense	29,172	20,319
Amortization of intangible assets	23,514	23,514
Interest expense	11,398	8,688
Other (income) expense, net	63	13
Income (loss) before income taxes	(36,769)	(7,291)
Operating Segments
Net revenues:
Net revenues	270,593	204,179
Segment profit (loss):
Segment profit (loss)	27,378	45,243
Medicare
Net revenues:
Net revenues	208,200	169,485
Medicare | Operating Segments
Net revenues:
Net revenues	265,331	196,853
Segment profit (loss):
Segment profit (loss)	27,046	45,812
Internal channel | Operating Segments
Net revenues:
Net revenues	203,845	157,353
Segment profit (loss):
Segment profit (loss)	34,839	46,443
External channel | Operating Segments
Net revenues:
Net revenues	61,486	39,500
Segment profit (loss):
Segment profit (loss)	(7,793)	(631)
Individual and Family Plan and Other | Operating Segments
Net revenues:
Net revenues	5,262	7,326
Segment profit (loss):
Segment profit (loss)	332	(569)
Internal channel | Operating Segments
Net revenues:
Net revenues	4,200	3,975
Segment profit (loss):
Segment profit (loss)	590	(729)
External channel | Operating Segments
Net revenues:
Net revenues	1,062	3,351
Segment profit (loss):
Segment profit (loss)	$ (258)	$ 160

Operating Segments and Signif_5

Operating Segments and Significant Customers - Summary of Revenue by Major Customers by Reporting Segments (Details) - Revenue - Customer concentration risk	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Anthem
Revenue, Major Customer [Line Items]
Revenue percent	25.00%	30.00%
Humana
Revenue, Major Customer [Line Items]
Revenue percent	24.00%	28.00%
United
Revenue, Major Customer [Line Items]
Revenue percent	18.00%	18.00%
Centene
Revenue, Major Customer [Line Items]
Revenue percent	15.00%	16.00%
Aetna
Revenue, Major Customer [Line Items]
Revenue percent	10.00%	1.00%